Skip to content

Metoclopramide Versus Placebo for GJ Placement

A Randomized Controlled Trial of Metoclopramide Versus Placebo During Gastrojejunostomy Tube Placement for Facilitating Guidewire Advancement Through the Pylorus

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03331965
Enrollment
110
Registered
2017-11-06
Start date
2018-04-09
Completion date
2019-10-03
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enteral Nutrition, Radiation Exposure

Keywords

Interventional Radiology, Metoclopramide, Gastrojejenostomy

Brief summary

The goal of this study is to determine whether use of promotility agents to stimulate gastric peristalsis can reduce fluoroscopy time and procedure time during gastrojejunostomy (GJ) tubes placement in interventional radiology (IR). The investigators hypothesize that increased gastric peristalsis will aid in advancing a guidewire through the pylorus, a time consuming and tedious step required during GJ tube placement. In order to maximize scientific rigor and clinical practice impact, the investigators aim to answer this question through a blinded, randomized, placebo controlled trial. Specific Aim 1: To test the hypothesis that a single dose of IV metoclopramide immediately prior to GJ tube placement reduces the fluoroscopy time required to advance a guidewire through the pylorus. Specific Aim 2: To determine whether a single dose of IV metoclopramide immediately prior to GJ tube placement reduces total procedure fluoroscopy time, air kerma and total procedure time. Specific Aim 3: To assess the safety of a single dose of promotility agent prior to GJ tube placement by assessing rates of adverse events in the periprocedural period in patients receiving IV metoclopramide versus placebo.

Detailed description

Gastrojejunostomy tube placement is a commonly performed procedure for providing nutritional support in patients unable to tolerate gastric feeds due to gastric outlet or duodenal obstruction or severe gastroesophageal reflux. When performed percutaneously, this procedure involves advancing a guidewire from the gastrostomy skin entry site through the pylorus. Based on data collected for quality improvement purposes the investigators have found that this step accounts for approximately one half the total fluoroscopy time and radiation dose during GJ tube placement and approximately one third of the total physician time in the procedure. Specifically, crossing the pylorus required on average 5.3 minutes of fluoroscopy time out of a total of 9.3 minutes for the entire procedure, and accounted for 92.2 mGy air kerma out of 201.7 mGy for the entire procedure. Furthermore, inability to advance a wire into the duodenum due to refractory pylorospasm is among the most common reasons for aborting GJ placement. Specifically, in approximately 1.5% of GJ placement procedures the pylorus cannot be crossed and a gastrostomy tube is placed instead. Only colonic interposition, in which GJ tube placement is not attempted, accounts for a larger fraction of failed procedures (3%). A variety of wire, catheter, and device related techniques have been described to facilitate wire intubation of the pylorus, but this remains a rate limiting step in the procedure. In order to reduce radiation doses to both the patient and interventional radiologist to levels that are as low as reasonably achievable and to maximize procedural success rates, adjunctive methods to aid in wire intubation of the pylorus are needed. Previous meta-analyses of randomized controlled trials have found that a single dose of erythromycin or metoclopramide is effective at emptying the stomach of blood and improving visualization during endoscopy for upper gastrointestinal tract bleeding. Similarly, a previous randomized controlled trial demonstrated that a single dose of metoclopramide or domperidone increases the rate at which nasoenteric tubes spontaneously pass through the pylorus from 27 to 55%. Single dose metoclopramide is also indicated for reducing transit time during small bowel follow through examinations. Drug related adverse events in these studies were rare. Although single dose promotility agents are established in the above described settings, they have not been studied for GJ tube placement. The investigators hypothesize that use of promotility agents may facilitate advancement of the guidewire through the duodenum and into the proximal jejunum during GJ tube placement by enhancing gastric peristalsis, pylorus relaxation, and small bowel motility. Single doses of promotility agents such as metoclopramide are inexpensive (approximately $1.02 per dose), easily administered at the time of the procedure, and have very favorable safety profiles. Therefore, promotility agents may represent a simple, effective, and readily feasible means of reducing radiation dose and procedure time during GJ tube placement, thus improving the safety and efficiency of this common IR procedure.

Interventions

DRUGMetoclopramide 5 MG/ML Injectable Solution

A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.

DRUGSaline

A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years old or older * undergoing de novo GJ placement as part of their routine clinical care

Exclusion criteria

* Patient pregnant * Contraindications to metoclopramide including: * allergic reaction * pheochromocytoma * QTc prolongation * history of seizure disorder * extrapyramidal symptoms

Design outcomes

Primary

MeasureTime frameDescription
Time to Duodenal IntubationUp to 45 minutes.The fluoroscopy time required to advance a guidewire through the pylorus.

Secondary

MeasureTime frameDescription
Total Procedure Fluoroscopy TimeUp to 1 hour.The total procedure fluoroscopy time.
Total Procedure Air KermaUp to 1 hour.The total procedure Air Kerma (energy released in a unit mass of air) measured in milligray (mGy).
Total Procedure TimeUp to 1 hour.The total procedure time.

Other

MeasureTime frameDescription
Number of Subjects Experiencing Adverse Effects in the Periprocedural PeriodUp to 30 days after procedure.To assess the safety of a single dose of promotility agent prior to GJ tube placement by assessing rates of adverse events in the periprocedural period in patients receiving IV metoclopramide versus placebo.

Countries

United States

Participant flow

Participants by arm

ArmCount
Metoclopramide
A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion. Metoclopramide 5 MG/ML Injectable Solution: A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
45
Saline
A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion. Saline: A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
51
Total96

Baseline characteristics

CharacteristicSalineTotalMetoclopramide
Age, Continuous53.8 years
STANDARD_DEVIATION 17.7
55.3 years
STANDARD_DEVIATION 18.3
56.9 years
STANDARD_DEVIATION 19
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
50 Participants94 Participants44 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Black or African American
11 Participants18 Participants7 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
40 Participants77 Participants37 Participants
Sex: Female, Male
Female
23 Participants38 Participants15 Participants
Sex: Female, Male
Male
28 Participants58 Participants30 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 450 / 51
other
Total, other adverse events
0 / 450 / 51
serious
Total, serious adverse events
0 / 450 / 51

Outcome results

Primary

Time to Duodenal Intubation

The fluoroscopy time required to advance a guidewire through the pylorus.

Time frame: Up to 45 minutes.

Population: Participants who completed the study.

ArmMeasureValue (MEAN)
MetoclopramideTime to Duodenal Intubation1.6 Minutes
SalineTime to Duodenal Intubation4.1 Minutes
Secondary

Total Procedure Air Kerma

The total procedure Air Kerma (energy released in a unit mass of air) measured in milligray (mGy).

Time frame: Up to 1 hour.

Population: Participants who completed the study.

ArmMeasureValue (MEAN)
MetoclopramideTotal Procedure Air Kerma91 mGy
SalineTotal Procedure Air Kerma130 mGy
Secondary

Total Procedure Fluoroscopy Time

The total procedure fluoroscopy time.

Time frame: Up to 1 hour.

Population: Participants who completed the study.

ArmMeasureValue (MEAN)
MetoclopramideTotal Procedure Fluoroscopy Time5.8 Minutes
SalineTotal Procedure Fluoroscopy Time8.8 Minutes
Secondary

Total Procedure Time

The total procedure time.

Time frame: Up to 1 hour.

Population: Participants who completed the study.

ArmMeasureValue (MEAN)
MetoclopramideTotal Procedure Time16.4 Minutes
SalineTotal Procedure Time19.9 Minutes
Other Pre-specified

Number of Subjects Experiencing Adverse Effects in the Periprocedural Period

To assess the safety of a single dose of promotility agent prior to GJ tube placement by assessing rates of adverse events in the periprocedural period in patients receiving IV metoclopramide versus placebo.

Time frame: Up to 30 days after procedure.

Population: Participants who completed the study.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
MetoclopramideNumber of Subjects Experiencing Adverse Effects in the Periprocedural Period0 Participants
SalineNumber of Subjects Experiencing Adverse Effects in the Periprocedural Period0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026